BioSpace News Archive

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced financial results for the second quarter ended Ju

AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, announced today that the Company has commenced operations of its new Philadelphia lab, with the completion of its facility renovation and first phase equipment installation in July 2020.

Soliton, Inc., (Nasdaq: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary platform technology, today reported financial results for the second quarter ended June 30, 2020 .

Tony Hale opens up about his personal experiences to help educate other asthma sufferers on the importance of personalized care

• Obtained U.S. FDA Fast Track designation for BDTX-189 for the treatment of adult patients with a solid tumor harboring an allosteric HER2 mutation or an EGFR or HER2 Exon 20 insertion mutation • Continued to enroll and dose patients in Phase 1/2 clinical trial of BDTX-189, with Phase 1 portion on track to complete by first half of 2021 • Strengthened executive team with the appointment of Fang Ni, Pharm.D., as Chief Business Officer • Cash, cash equivalents, and in

Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that it has commenced its previously disclosed rights offering.

ReShape Lifesciences Inc., a leading developer and distributor of minimally invasive medical devices to treat obesity and metabolic diseases, announced that it will report its second quarter 2020 financial and operational results on Thursday, August 13, 2020 after the close of the U.S. financial markets.

AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announces that its wholly-owned research and development subsidiary, Sapphire Biotech, Inc.

A chorus of expert female voices, including caucus co-chairs Reps. Brenda Lawrence, Debbie Lesko, Vice-Chair Madeleine Dean, and Jedediah Bila of Fox & Friends Weekend to tackle growing concerns

Researchers at the Washington University School of Medicine in St. Louis, Mo., led by neurosurgeon Dr. Albert H. Kim, found direct evidence in mice that the focal thermal effect of laser interstitial thermal therapy opens the blood-brain barrier and blood-tumor barrier.